In plain language
SS-31, known in clinical development as elamipretide, is a mitochondria-targeting peptide studied for diseases involving mitochondrial dysfunction, including some heart and rare mitochondrial conditions. It has reached human trials, but results have been mixed and it is not approved. Longevity claims go beyond the current evidence.
What it is explored for
SS-31 stands out because it targets the mitochondria directly, and it has advanced further into human trials than most peptides in its class. Results so far are mixed and it remains unapproved, but its focus on cellular energy and antioxidant protection keeps it a genuinely interesting area of study.
- Mitochondrial energy and ATP production
- Reducing oxidative stress from reactive oxygen species
- Supporting mitochondrial membrane stability
- Cardiac function in heart-related research
- Neuroprotection and resilience of nerve tissue
- Recovery and anti-inflammatory pathways
These are areas of active interest and reported use, not proven outcomes. This peptide carries a preliminary evidence rating, see the evidence summary below for how strong the science actually is.
How it works
SS-31 concentrates in the inner mitochondrial membrane, where it interacts with the lipid cardiolipin. This is proposed to stabilize mitochondrial function under stress.
- Cardiolipin binding. Associates with cardiolipin in the inner mitochondrial membrane, which may help maintain efficient energy production.
- Reduced oxidative stress. Reported to lower reactive oxygen species and protect mitochondrial structure in stressed tissues.
- Targeted to mitochondria. Its design lets it accumulate selectively in mitochondria, the focus of its proposed therapeutic effect.
Mechanistic data are supported by preclinical work, but human trial results have been mixed and no benefit is firmly established.
Evidence summary
SS-31/elamipretide has advanced into multiple human trials for mitochondrial and cardiac conditions, which is further than most research peptides. Results have been inconsistent and it is not approved, so evidence for any specific benefit, especially longevity, remains preliminary.
Reported safety & side effects
In trials, injection-site reactions are commonly reported. Overall safety appeared manageable in studied populations, but it is not an approved drug and long-term safety is not established.
Frequently asked
Has SS-31 been tested in humans?
Yes. As elamipretide it has been studied in multiple clinical trials, but results have been mixed and it has not received approval.
Is SS-31 proven for anti-aging?
No. Its trials targeted specific mitochondrial and cardiac conditions, not aging. Longevity claims are not supported by the evidence.